![share_log](https://pubimg.futunn.com/2021072603057812ae5b65e388b.png?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Altamira Therapeutics | 20-F/A: FY2023 Annual Report
Altamira Therapeutics | 20-F/A: FY2023 Annual Report
Altamira Therapeutics | 20-F/A:2023財年年報
牛牛AI助理已提取核心訊息
Altamira Therapeutics, a biopharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company's revenue for the year was recorded at $158,213, primarily generated from the sale of Bentrio®, a nasal spray for protection against airborne allergens. However, the company faced a gross loss of $67,676 after accounting for the cost of sales, which amounted to $225,889. The operating loss stood at $1,731,453, with research and development expenses contributing significantly at $1,425,373. Selling, general, and administrative expenses were reported at $372,479. The net loss attributable to owners of the company was $1,779,505, with a total comprehensive loss of $1,640,922 after considering foreign currency translation differences. The company's business development efforts included the completion of a clinical trial for Bentrio® in Australia and...Show More
Altamira Therapeutics, a biopharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company's revenue for the year was recorded at $158,213, primarily generated from the sale of Bentrio®, a nasal spray for protection against airborne allergens. However, the company faced a gross loss of $67,676 after accounting for the cost of sales, which amounted to $225,889. The operating loss stood at $1,731,453, with research and development expenses contributing significantly at $1,425,373. Selling, general, and administrative expenses were reported at $372,479. The net loss attributable to owners of the company was $1,779,505, with a total comprehensive loss of $1,640,922 after considering foreign currency translation differences. The company's business development efforts included the completion of a clinical trial for Bentrio® in Australia and the launch of the product in certain markets, including Germany. Altamira Therapeutics also entered into an exclusive licensing and distribution agreement with Nuance Pharma for Bentrio® in Mainland China, Hong Kong, Macau, and South Korea, which included an upfront payment of $1 million. Looking ahead, Altamira Therapeutics plans to continue its efforts to grow product revenues, generate additional licensing revenues, and, if necessary, raise further funds to maintain adequate cash reserves. The company's future profitability is expected to depend on the product's market uptake, regulatory approvals, and the conclusion of additional distribution or licensing agreements.
生物製藥公司Altamira Therapeutics報告了截至2023年12月31日財政年度的年度財務業績。該公司營業收入爲158,213美元,主要來自對抗空氣過敏原鼻噴藥Bentrio®的銷售。然而,經過考慮銷售成本,該公司錄得了67,676美元的毛虧損,銷售成本總計爲225,889美元。營業虧損達到了1,731,453美元,研發費用對此做出了重要貢獻,爲1,425,373美元。銷售、普通和行政費用報告爲372,479美元。該公司所有者的淨虧損爲1,779,505美元,考慮到外幣翻譯差異後的總綜合虧損爲1,640,922美元。該公司的業務拓展工作包括在澳洲完成Bentrio®的臨床試驗,以...展開全部
生物製藥公司Altamira Therapeutics報告了截至2023年12月31日財政年度的年度財務業績。該公司營業收入爲158,213美元,主要來自對抗空氣過敏原鼻噴藥Bentrio®的銷售。然而,經過考慮銷售成本,該公司錄得了67,676美元的毛虧損,銷售成本總計爲225,889美元。營業虧損達到了1,731,453美元,研發費用對此做出了重要貢獻,爲1,425,373美元。銷售、普通和行政費用報告爲372,479美元。該公司所有者的淨虧損爲1,779,505美元,考慮到外幣翻譯差異後的總綜合虧損爲1,640,922美元。該公司的業務拓展工作包括在澳洲完成Bentrio®的臨床試驗,以及在包括德國在內的某些市場上推出該產品。Altamira Therapeutics還與Nuance Pharma在中國大陸、香港、澳門和韓國簽訂了Bentrio®的獨家許可和分銷協議,其中包括一筆100萬美元的前期付款。展望未來,Altamira Therapeutics計劃繼續努力增加產品收入,產生額外的許可收入,如有必要,籌集進一步的資金以維持足夠的現金儲備。該公司未來的盈利預計將取決於產品市場接受度、監管批准以及其他分銷或許可協議的完成。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了